Skip to content

Clinical Observation and Mechanism Study of Low-dose Intralesional Injection of 5-Fluorouracil and Triamcinolone in the Treatment of Chronic Eczema

Clinical Observation and Mechanism Study of Low-dose Intralesional Injection of 5-Fluorouracil and Triamcinolone in the Treatment of Chronic Eczema

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043660
Enrollment
Unknown
Registered
2021-02-25
Start date
2018-01-31
Completion date
Unknown
Last updated
2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eczema

Interventions

5-FU+TA group:2 mL normal saline (Shanghai Xudong Haipu Pharmaceutical Co., Ltd.) was mixed well with 1 mL 5-FU solution (Shanghai Xudong Haipu Pharmaceutical Co., Ltd.) (containing 25 mg 5-FU) and 1
TA group:3 mL of normal saline was mixed with 1 mL of TA solution (containing 10 mg TA).Infiltration and injection were performed to allow 1 mL of the mixture into every 4 cm2 of the skin lesion area.

Sponsors

Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
28 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 28 to 80 years old, who have given birth; 2. Meet the clinical diagnostic criteria of localized eczema, established based on the 2011 Guidelines for Eczema Diagnosis and Treatment designated by the Immunology Group, Dermatovenereology Society, Chinese Medical Association; 3. Continue Onset, duration of disease> 6 months; 4. The results of the 20 patch tests in the routine group were all negative; 5. The skin lesions had no infection or exudation; 6. The patient had good compliance, was willing to adhere to the treatment and complete the follow-up, and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to triamcinolone acetonide or 5-FU; 2. Pregnant women or breastfeeding women, or those who plan to give birth or have not given birth within 12 months; 3. Hepatic and renal function test results are abnormal; 4. Hematological diseases, autoimmune diseases, chronic serious Sexual infections, diabetes, mental illness, alcoholism, malignant tumors and other serious diseases; 5. Systematic use of hormones or immunosuppressants in the past 6 weeks, and topical medication in the past 2 weeks.

Design outcomes

Primary

MeasureTime frame
atopic dermatitis severity index (ADSI) score;Relapse rate;

Secondary

MeasureTime frame
effctive rate;

Countries

China

Contacts

Public ContactYUN WU

Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital

verawuyun@163.com+86 13918129724

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026